Tryp Therapeutics trades on the FSE under the symbol
About
Tryp Therapeutics is a pharmaceutical company focused on developing psilocybin-based compounds for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. Tryp's Psilocybin-For-Neuropsychiatric Disorders (PFN™) program is focused on the development of synthetic psilocybin as a new class of drug for the treatment of chronic pain and other indications. The Company has announced upcoming Phase 2a clinical trials with the University of Michigan and the University of Florida to evaluate its drug products for fibromyalgia and overeating disorders, respectively. Tryp is also developing a proprietary psilocybin-based product, TRP-8803, that uses a novel formulation and route of administration to improve the patient experience.
Leadership Team
The TRYP Management team has decades of experience building successful pharmaceutical and biotech companies together, and bring a balanced combination of capital markets experience, Big Pharma and FDA expertise (having successfully brought drugs to market), and a track record of building profitable public companies.
Greg McKee, CEO & Chairman
Extensive experience leading publicly traded pharmaceutical companies and brings a vast network of relationships in the life science industry.
Began his life science career at Genzyme where he was responsible for commercializing leading compounds for rare diseases throughout Asia.
Chairman and CEO of Nventa Biopharmaceuticals Corporation and Akela Pharma Inc., both publicly traded biopharmaceutical companies.
CEO of CONNECT, an early stage incubator, and as Managing Director at Torrent Ventures.
Was previously appointed as Chairman of the Board of Directors of Tryp in February 2021.
William Garner, Executive Chairman
Founder of Race Oncology (ASX:RAC)
Co-Founder and Director of DelMar Pharmaceuticals (NASDAQ:DMPI)
Founder of EGB Ventures, where he was focused on advancing technologies and companies to monetization or assets via licensing, mergers and acquisitions or IPO transactions.
Previous Big Pharma experience at Pfizer & QLT leading larger partnerships & product portfolios.
MBA, Vanderbilt University & BSc in Chemistry from Loyola University, Chicago
Dr. Jim Gilligan, President & Chief Science Officer
PhD from the University of Connecticut & MBA from Seton Hall University
Over 35 years of experience in the life sciences industry, including R&D, clinical development, international regulatory affairs, and CMC manufacturing.
Co-Founder of Unigene Laboratories
Co-Founder & Chief Science Office of Tarsa Therapeutics
James Kuo, Director
Chairman of the Board, ImmunoPrecise Antibodies (TSXV:IPA).
Former Managing Director of HealthCare Ventures, a $378 Million venture capital fund.
Former CEO of BioMicro Systems and Discovery Laboratories.
Former Associate Director of Licensing and Development at Pfizer.
MD from University of Pennsylvania School of Medicine.
MBA from the Wharton School of Business.
Pipeline / Market Opportunities
TRYP’s PFN™ Program
Tryp’s PFN™ program is focused on developing orally-delivered drug therapies for certain neuropsychiatric disorders that have distinct advantages over other drugs that are currently in the market or are in development.
TRP-8802 | Fibromyalgia
Chronic and debilitating CNS/neurobiological disorder. The fibromyalgia treatment market is estimated to surpass US$3.6B by 2026.
TRP-1001 | Razoxane (Soft Tissue Sarcomas)
Oncology is the leading therapeutic category and represented 25% of all drug sales in 2018, which equated to ~US$151B in 2018.
